Disease · MONDO_0004989
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Tuc+Cap+Tra vs Pbo+Cap+Tra: deaths from any cause | 262 of 410 | 152 of 202 | 612 | NCT02614794 | Trial comparisons |
| Tuc+Cap+Tra vs Pbo+Cap+Tra: serious adverse events | 124 of 404 | 62 of 197 | 601 | NCT02614794 | Trial comparisons |
| Tucatinib+ Ado-trastuzumab Emtansine vs Placebo+ Ado-trastuzumab Emtansine: Number of Participants With Treatment Emergent Adverse Events (AEs) | 230 of 231 | 233 of 233 | 464 | NCT03975647 | Trial comparisons |
| Placebo+ Ado-trastuzumab Emtansine vs Tucatinib+ Ado-trastuzumab Emtansine: deaths from any cause | 63 of 233 | 71 of 231 | 464 | NCT03975647 | Trial comparisons |
| Placebo+ Ado-trastuzumab Emtansine vs Tucatinib+ Ado-trastuzumab Emtansine: serious adverse events | 52 of 233 | 70 of 231 | 464 | NCT03975647 | Trial comparisons |
| Cisplatin and Cetuximab vs Cisplatin: Safety- Number of Participants Experiencing Any Adverse Event (AE) | 114 of 114 | 57 of 57 | 171 | NCT00463788 | Trial comparisons |
| Colorectal Cancer vs Non-Colorectal Cancer Cohort vs Breast and Ovarian Cohorts: deaths from any cause | 1 of 25 | 0 of 26 | 51 | NCT00088413 | Trial comparisons |
Colorectal Cancer and Non-Colorectal Cancer Cohort vs Breast Cancer and Ovarian Cancer Cohort: Number of Participants With Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE) v3.0 and v4.0 | 25 of 25 | 26 of 26 | 51 | NCT00088413 | Trial comparisons |
| Colorectal Cancer vs Non-Colorectal Cancer Cohort vs Breast and Ovarian Cohorts: serious adverse events | 25 of 25 | 26 of 26 | 51 | NCT00088413 | Trial comparisons |
| Dose Level 1 - Docetaxel 75 mg/m^2 vs Dose Level 2 - Docetaxel 60 mg/m^2: serious adverse events | 2 of 2 | 7 of 29 | 31 | NCT00086957 | Trial comparisons |
Colorectal Cancer Cohort vs Non-Colorectal Cancer Cohort: Number of Participants With an Positive Immune Response to Carcinoembryonic Antigen (CEA) Peptide and/or Protein in the Colorectal Cancer and Non-colorectal Cancer Cohort Post Vaccination | 3 of 9 | 6 of 9 | 18 | NCT00088413 | Trial comparisons |
Breast Cancer Cohort vs Ovarian Cancer Cohort: Number of Participants With an Positive Immune Response to Carcinoembryonic Antigen (CEA) Peptide and/or Protein in the Breast Cancer and Ovarian Cancer Cohorts Post Vaccination | 1 of 3 | 1 of 2 | 5 | NCT00088413 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004989/comparisons